Regulatory Filings • Oct 11, 2017
Regulatory Filings
Open in ViewerOpens in native device viewer
STOCKHOLM, October 11, 2017 – Michigan-based McLaren Health Care and Elekta (EKTA-B.ST) have mutually agreed to terminate their business agreement from December 2013. McLaren Health Care and Elekta will continue their business relationship but on a smaller scale.
In accordance with its process for constant review of backlog, Elekta has therefore determined to reduce USD 72 million of the backlog, to be reported in Q2 fiscal year 2017/18. There will be no material effect on Elekta's results.
For further information, please contact: Gert van Santen, Group Vice President Corporate Communications, Elekta AB Tel: +31 653 561 242, e-mail: [email protected] Time zone: CET: Central European Time
Tobias Bülow, Director Financial Communications, Elekta AB Tel: +46 722 215 017, e-mail: [email protected] Time zone: CET: Central European Time
This is information that Elekta AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication at 07:30 CET on October 11, 2017. (REGMAR)
Elekta is proud to be the leading innovator of equipment and software used to improve, prolong and save the lives of people with cancer and brain disorders. Our advanced, effective solutions are created in collaboration with customers, and more than 6,000 hospitals worldwide rely on Elekta technology. Our treatment solutions and oncology informatics portfolios are designed to enhance the delivery of radiation therapy, radiosurgery and brachytherapy, and to drive cost efficiency in clinical workflows. Elekta employs 3,600 people around the world. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm. www.elekta.com
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.